InflaRx N.V. announced on February 28, 2025, that all submitted abstracts featuring vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) have been accepted for presentation. These presentations will occur during the 2025 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 7-11 in Orlando, FL.
The accepted abstracts reflect the scientific work invested in the clinical development of vilobelimab for these inflammatory conditions. Notably, the company will present new data on the reduction in draining tunnels (dTs) with vilobelimab in HS.
The presentations will also cover the relevance of InflaRx's modified HiSCR, which emphasizes the impact of dTs on HS patients. This event provides an opportunity to showcase vilobelimab's potential to the dermatology community and investors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.